ImpediMed Limited (ASX:IPD)
has announced it has entered into a 5 year master clinical trial agreement with the Mayo Clinic.
The trial will explore additional indications for its fluid status and body composition monitoring technology.
Clinical trials will be conducted at multiple U.S. locations and will also explore if the ImpediMed technology has wider applications in cardiology, nephrology, wellness and fitness.
Interim results from the trials are expected to be released late 2016.
ImpediMed Limited reported a net loss of $11.2 million at 31 December 2015.